uniQure shares swing after AMT-130 approval filing; Blair resumes coverage
uniQure (QURE) shares swung after the company filed for U.S. and U.K. approval of its Huntington’s disease gene therapy, AMT-130. William Blair resumed coverage with an Outperform rating and a $73 fair value estimate.